期刊
EUROPEAN JOURNAL OF HEART FAILURE
卷 17, 期 6, 页码 544-558出版社
WILEY
DOI: 10.1002/ejhf.289
关键词
Acute heart failure; cardiogenic shock; diuretics; vasodilators
资金
- Bayer
- Cardiorentis
- Medicine Company
- Critical Diagnostics
- Novartis
- Steering Committee member of Cardiorentis
- TUBITAK
- Medicines Company
- Cornerstone Therapeutics
- Otsuka
- Janssen
- Apex Innovations
- Inte-Section Medical
- Trevena
- Vifor Pharma Ltd
- Amgen
- Servier
- Abbott Vascular
- Coridea
- Respicardia
- Swiss National Science Foundation
- Swiss Heart Foundation
- Cardiovascular Research Foundation Basel
- 8sense
- Abbott
- ALERE
- Brahms
- Nanosphere
- Roche
- Siemens
- University Hospital Basel
- Astra Zeneca
- BG medicine
- Biomerieux
- Lilly
- Orion
- Resmed
- Roche Diagnostics
- Ratiopharm
- BMS
- Boehringer-Ingelheim
- Pfizer
- Daiichi Sankyo
- Boehinger Ingelheim
- AstraZeneca
- European Union
Acute heart failure is a fatal syndrome. Emergency physicians, cardiologists, intensivists, nurses and other health care providers have to cooperate to provide optimal benefit. However, many treatment decisions are opinion-based and few are evidenced-based. This consensus paper provides guidance to practicing physicians and nurses to manage acute heart failure in the pre-hospital and hospital setting. Criteria of hospitalization and of discharge are described. Gaps in knowledge and perspectives in the management of acute heart failure are also detailed. This consensus paper on acute heart failure might help enable contiguous practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据